Combination pharmacotherapy improves neurological outcome after asphyxial cardiac arrest

Intraarrest Rhythms and Rhythm Conversion in Asphyxial Cardiac Arrest

“…The observed VF frequency (63%) at 4 minutes of ACA is significantly different when compared to the reported frequency of nonasphyxial VF cardiac arrest (≤ 30%; p < 0.001, using exact binomial testing). 12,15 Due to the small number of animals with asystole, statistical comparisons between this group and the other groups were not performed. However, we found a trend between time to cardiac arrest and initial cardiac arrest rhythm; the time to cardiac arrest in animals with asystole (10.87 AE 0.17 minutes) was longer compared to animals with PEA (8.26 AE 1.60 minutes) and VF (7.29 AE 0.67 minutes), with the difference between VF and PEA groups being not statistically significant.…”

“…12,15 When compared to the frequency of nonasphyxial VF cardiac arrest (≤30%), we estimated that 30 animals would be a sufficient sample size to establish the desired increase in VF frequency (from 30% to 60%) with 90% power, at the alpha = 5% significance level, using exact binomial testing. Power analysis was conducted using Power Analysis and Sample Size (PASS, version 13) for Windows.…”

“…[9][10][11][12][13][14][15][16] Recent evidence suggests that ventricular fibrillation (VF) is more common than was originally believed in the setting of out-of-hospital asphyxial cardiac arrest (ACA), 11 while it is becoming a more frequent presenting arrest rhythm to emergency departments. 12,13 Moreover, the incidence of VF in pediatric cardiac arrest varies between 4 and 23%. 14 However, data about the pathophysiology of ACA in children remain scarce.…”

“…The objective of this study was to analyze, in an animal model, the cardiac arrest rhythms presenting during ACA. 12 …”

How Can we Study Cardiopulmonary Resuscitation and Cardiac Arrest in Animals: a Review

“…In addition to the clinical evaluation of neurological function, histopathological damages are also usually evaluated in most experimental studies [62]. End-points could be the number of ischemic neurons [51] and the presence of other abnormalities such as edema or congestion of capillaries [33,63]. Several circulating biomarkers of brain lesions could also be evaluated in animals as surrogate markers such as neuron specific enolase [64] and protein S100 [65].…”